All News

Investigators wanted to answer the question, “Is incident myocardial infarction associated with cognitive function changes compared with pre-MI cognition trajectories?”

Biden administration finalizes a deal on covering preventive care despite legal battle; CMS prepares safety net hospital reimbursement plans; over 1 million Americans have been dropped from Medicaid coverage

Fundus photographs of eyes with diabetic macular edema (DME) could be used to estimate best-corrected visual acuity (BCVA) when artificial intelligence examines the pictures.

Using race-neutral rather than race and ethnicity-specific reference equations to interpret pulmonary function tests (PFTs) increased the number of Black individuals considered to have respiratory impairments, suggesting that race and ethnicity-specific equations may reinforce health disparities.

This international study looked at educational outcomes among adolescents with eczema as influenced by their quality of life living with the chronic inflammatory skin condition.

A longer length of hospitalization suggests how racial disparities may affect minority patients with severe respiratory illnesses.

Nirsevimab was unanimously recommended by the FDA Advisory Committee for immunization against respiratory syncytial virus (RSV) in infants.

Mark Fendrick, MD, and Nicholas Bagley, JD, discuss how the ruling in Braidwood v Becerra could affect availability of preventive care.

The Biden administration will impose drug price inflation penalties on drugmakers; a study reveals massive amounts of COVID-19 relief funds were stolen; experimental vaccine nearly doubles survival in patients in a trial.

Moving to co-administration could also help more adults catch up with vaccination recommendations, the authors said.

Courtney DiNardo, MD, MSCE, the lead author on a study presented at EHA 2023 evaluating a new therapy for chronic myelomonocytic leukemia and acute myeloid leukemia, discusses the FDA Fast Track Designation for IO-202 and strategies for raising awareness and improving diversity in clinical trials.

Panelists provided a wide-ranging view of the current avenues being investigated to optimize the treatment of chronic lymphocytic leukemia (CLL), including minimal residual disease assessment, combination regimens, and chimeric antigen receptor T-cell therapy.

Martin Griesshammer, MD, PhD, from the Johannes Wesling University Clinic, spoke on the current unmet needs in treating polycythemia vera (PV) and how multistakeholder collaboration can help address them.

More data is emerging on the efficacy of several triplet therapies to treat single-class refractory multiple myeloma (MM), potentially giving patients more therapy options than ever before, according to Tel-Aviv Sourasky Medical Center's Yael Cohen, MD, at the European Hematology Association 2023 Congress.

Wojciech Jurczak, MD, PhD, lead researcher on the L-MIND study evaluating a new treatment combination in diffuse large B-cell lymphoma (DLBCL), gave an overview of the trial results that were presented at the European Hematology Association 2023 Congress.

The late-breaking oral session at the European Hematology Association (EHA) 2023 Congress featured newly emerged data from abstracts submitted after the deadline, including outcomes from trials in polycythemia vera, acute myeloid leukemia, and more.

Results are based on a series of surveys completed by 17 experts.

In a 6-month trial, more than 85% of adults on CBD showed significant reduction in the number of monthly seizures, suggesting this treatment may be an effective adjuvant option.

Patients with the rare disease typically present with hypertrophic cardiomyopathy and muscular hypotonia before the age of 1.

Findings are based on a retrospective, multicenter study carried out in Spain.

Newly presented data reveal disparities between Black and White patients in both the characteristics of and the decision-making around treatment for chronic lymphocytic leukemia (CLL) and multiple myeloma, respectively.

With the number of treatment options in hematology and oncology rapidly expanding, so too are the strategies for determining and ensuring cost-effectiveness, according to session speakers at the European Hematology Association (EHA) 2023 Congress.

Findings are based on a case-control study carried out in Brazil.

The first phase 3 results from the CARTITUDE-4 trial of ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory multiple myeloma (MM) demonstrated the former’s convincing superiority in several key outcomes.

Results from the ASPEN and ALPINE trials of zanubrutinib showed greater improvements in quality of life (QOL) vs ibrutinib.

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic lymphocytic leukemia (CLL) and what providers should keep in mind before prescribing them.

MD Anderson Cancer Center's Hans Lee, MD, shared considerations for possible infection risk associated with bispecific therapies used to treat relapsed/refractory multiple myeloma (MM) at the European Hematology Association 2023 Congress

An analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) deficiency mutations showed that patients with BRCA mutations had poor outcomes compared with those without BRCA mutations and those with non-BRCA HRR mutations.

James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains how nerve and muscle signaling in the neuromuscular junction go awry in myasthenia gravis.

Skin rashes are common among patients who complete hematopoietic cell transplantation (HCT).